DeCure for X-linked mixed hearing loss with perilymphatic gusher
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for X-linked mixed hearing loss with perilymphatic gusher — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleX-linked mixed hearing loss with perilymphatic gusher maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for x-linked mixed hearing loss with perilymphatic gusher is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
In 1997, five patients with clinical and radiographic evidence of X-linked mixed deafness with perilymphatic gusher (DFN3) underwent molecular analysis of the POU3F4 gene. Novel mutations were found in two of the five patients; the other three had an entirely normal protein coding sequence. The authors concluded that not all patients with the characteristic phenotype have involvement of the POU3F4 gene. A 2012 review notes that POU3F4 was the first gene identified for nonsyndromic X-linked hearing loss, and that a second gene, PRPS1, has since been identified as the cause of DFNX1 (formerly DFN2). The review also states that 135 loci and 50 genes have been identified for nonsyndromic hearing loss overall.
A separate 1997 study tested immunosuppressive therapy with azathioprine (25 mg three times daily) plus prednisone (initial dose 20–40 mg, then 5–15 mg daily) in ten patients who had one deafened ear and developed progressive or fluctuant hearing loss in the only hearing ear. Perilymphatic fistula was excluded by tympanoscopy. Six of the ten subjects responded. The average pure tone audiogram (PTA) at speech frequencies in the treated ear improved from 57.3 dB HL to an average improvement of 22.4 dB HL after a mean treatment period of five weeks. The speech discrimination score (SDS) was 85% initially. In the contralateral ear (average PTA 72.5 dB HL, SDS 28%), the mean PTA improvement was insignificant at 4.4 dB. Vertigo improved in three of five patients who had it. The authors state that cortisone alone, or in combination with cyclophosphamide or ciclosporine, was not effective in their hands.
No study has tested azathioprine or any other drug in patients with X-linked mixed hearing loss with perilymphatic gusher specifically. The 1997 azathioprine trial involved patients with cochlear hydrops or Meniere’s disease, not DFN3. The molecular understanding of DFN3 remains incomplete: three of five patients in the 1997 genetic study had no POU3F4 mutation. What is missing is a trial designed for this specific population, funding for such a trial, and stratification of patients by genetic status.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Molecular Analysis of the Pou3F4 Gene in Patients with Clinical and Radiographic Evidence of X-Linked Mixed Deafness with Perilymphatic Gusher
AbstractThe molecular defect in some patients with X-linked mixed deafness with perilymphatic gusher at stapes surgery (DFN3) was recently attributed to mutations in the POU3F4 gene. In this manuscript we describe the molecular analysis of the POU3F4 gene in 5 patients with clinical and radiographic evidence of DFN3. Novel mutations were found in 2 of the 5 patients analyzed, while 3 had an entirely normal protein coding sequence. The fact that 3 of the 5 patients with clinical histories and radiographic abnormalities characteristic of X-linked mixed deafness with perilymphatic gusher displayed normal POU3F4 gene sequences supports the possibility that not all patients with the characteristic phenotype have involvement of the POU3F4 gene.
Azathioprine with Cortisone in Treatment of Hearing Loss in only Hearing Ear
AbstractA sudden or progressive hearing loss in the only hearing ear is an otologic emergency, in which therapeutic possibilities are limited. We describe results of immunosuppressive therapy in 10 patients with one deafened ear either due to cochlear hydrops or Meniere's disease, who developed progressive or fluctuant hearing loss in the only hearing ear. The perilymphatic fistula was excluded with tympanoscopy. Azathioprine (25 mg t.i.d.) with prednisone (initial dose 20-40 mg with daily dose of 5-15 mg/day) was used. The hearing of 6 subjects responded to treatment. The initial pure tone audiogram (PTA) at speech frequencies of the "only hearing ear" was 57.3 dB HL with speech discrimination score (SDS) of 85%. The hearing improvement occurred successively within days or weeks. The average improvement of PTA was 22.4 dB HL after the mean treatment period of 5 weeks. In contralateral ear (the average PTA and SDS were 72.5 dB HL and 28%, respectively) the mean improvement in PTA was insignificant (4.4 dB). In 5 patients with vertigo it was improved in 3 cases. Cortisone alone or with combination of cyclophosphamide or ciclosporine was not effective in our hands.
Frontiers in Bioscience-Elite · 2012 · 12 citations
Nonsyndromic X-linked hearing loss
AbstractTo date, 135 loci and 50 genes have been identified as causes of nonsyndromic hearing loss. Until recently, four loci (DFN2, DFN3, DFN4, and DFN6) had been implicated in nonsyndromic X-linked hearing loss; however, a new classification (DFNX1-5) has been proposed to reduce confusion in the terminology. The different types of nonsyndromic X-linked hearing loss demonstrate various clinical features in terms of the onset and progressiveness of hearing loss, pattern of audiogram, and the presence or absence of inner ear malformations. In addition to the POU3F4 gene, which was the first gene identified as causing nonsyndromic X-linked hearing loss, a second gene, PRPS1, has recently been identified to be the causative gene of DFNX1 (DFN2). This study reviews the new classification system, as well as the clinical features, molecular genetics, and developmental pathogenesis of different forms of nonsyndromic X-linked hearing loss.
AbstractX-Linked sensorineuronal hearing loss (SNHL) is a rare but recognized cause of bilateral SNHL associated with CSF gusher. We report a case presenting a varied imaging spectrum and clinical scenario of a one year old boy with unilateral profound hearing loss and recurrent meningitis due to spontaneous oval window gusher. Imaging showed a unilateral abnormality, with the fistula leaking from the oval window into the middle ear cleft.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
